These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
92 related articles for article (PubMed ID: 25320939)
1. [Drug-drug interaction with telaprevir or boceprevir in liver transplant patients: about four cases]. Delaborde L; Logerot S; Fonrose X Therapie; 2014; 69(6):491-7. PubMed ID: 25320939 [TBL] [Abstract][Full Text] [Related]
3. A small percentage of patients with hepatitis C receive triple therapy with boceprevir or telaprevir. Chen EY; Sclair SN; Czul F; Apica B; Dubin P; Martin P; Lee WM Clin Gastroenterol Hepatol; 2013 Aug; 11(8):1014-20.e1-2. PubMed ID: 23602817 [TBL] [Abstract][Full Text] [Related]
4. Safety and efficacy of protease inhibitors to treat hepatitis C after liver transplantation: a multicenter experience. Coilly A; Roche B; Dumortier J; Leroy V; Botta-Fridlund D; Radenne S; Pageaux GP; Si-Ahmed SN; Guillaud O; Antonini TM; Haïm-Boukobza S; Roque-Afonso AM; Samuel D; Duclos-Vallée JC J Hepatol; 2014 Jan; 60(1):78-86. PubMed ID: 23994384 [TBL] [Abstract][Full Text] [Related]
5. Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) - NCT01514890. Hézode C; Fontaine H; Dorival C; Larrey D; Zoulim F; Canva V; de Ledinghen V; Poynard T; Samuel D; Bourlière M; Zarski JP; Raabe JJ; Alric L; Marcellin P; Riachi G; Bernard PH; Loustaud-Ratti V; Métivier S; Tran A; Serfaty L; Abergel A; Causse X; Di Martino V; Guyader D; Lucidarme D; Grando-Lemaire V; Hillon P; Feray C; Dao T; Cacoub P; Rosa I; Attali P; Petrov-Sanchez V; Barthe Y; Pawlotsky JM; Pol S; Carrat F; Bronowicki JP; J Hepatol; 2013 Sep; 59(3):434-41. PubMed ID: 23669289 [TBL] [Abstract][Full Text] [Related]
6. Drug-drug interactions with oral anti-HCV agents and idiosyncratic hepatotoxicity in the liver transplant setting. Tischer S; Fontana RJ J Hepatol; 2014 Apr; 60(4):872-84. PubMed ID: 24280292 [TBL] [Abstract][Full Text] [Related]
7. Directly acting antivirals for hepatitis C and antiretrovirals: potential for drug-drug interactions. Seden K; Back D Curr Opin HIV AIDS; 2011 Nov; 6(6):514-26. PubMed ID: 22001895 [TBL] [Abstract][Full Text] [Related]
8. [Expert opinion on boceprevir- and telaprevir-based triple therapies of chronic hepatitis C]. Sarrazin C; Berg T; Cornberg M; Dollinger M; Ferenci P; Hinrichsen H; Klinker H; Kraus M; Manns M; Mauss S; Peck-Radosavljevic M; Schmidt H; Spengler U; Wedemeyer H; Wirth S; Zeuzem S Z Gastroenterol; 2012 Jan; 50(1):57-72. PubMed ID: 22222799 [TBL] [Abstract][Full Text] [Related]
9. The first wave: HCV NS3 protease inhibitors telaprevir and boceprevir. Marks KM; Jacobson IM Antivir Ther; 2012; 17(6 Pt B):1119-31. PubMed ID: 23188750 [TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetic interaction between the hepatitis C virus protease inhibitor boceprevir and cyclosporine and tacrolimus in healthy volunteers. Hulskotte E; Gupta S; Xuan F; van Zutven M; O'Mara E; Feng HP; Wagner J; Butterton J Hepatology; 2012 Nov; 56(5):1622-30. PubMed ID: 22576324 [TBL] [Abstract][Full Text] [Related]
11. Cost effectiveness of direct-acting antiviral therapy for treatment-naive patients with chronic HCV genotype 1 infection in the veterans health administration. Chan K; Lai MN; Groessl EJ; Hanchate AD; Wong JB; Clark JA; Asch SM; Gifford AL; Ho SB Clin Gastroenterol Hepatol; 2013 Nov; 11(11):1503-10. PubMed ID: 23707354 [TBL] [Abstract][Full Text] [Related]
12. Anemia management in patients with chronic viral hepatitis C. Hynicka LM; Heil EL Ann Pharmacother; 2013 Feb; 47(2):228-36. PubMed ID: 23386076 [TBL] [Abstract][Full Text] [Related]
13. Future of hepatitis C therapy: development of direct-acting antivirals. Dore GJ; Matthews GV; Rockstroh J Curr Opin HIV AIDS; 2011 Nov; 6(6):508-13. PubMed ID: 21897228 [TBL] [Abstract][Full Text] [Related]
14. Future perspectives: towards interferon-free regimens for HCV. Gane E Antivir Ther; 2012; 17(6 Pt B):1201-10. PubMed ID: 23186654 [TBL] [Abstract][Full Text] [Related]
15. [Israeli guidelines for the treatment of chronic hepatitis C infection--2012 Israeli Association for the Study of the Liver]. Zuckerman E; Safadi R; Oren R; Shibolet O; Baruch Y; Bruck R; Lurei Y; Kaspa RT; Abu-Mouch S; Shouval D; Ben-Ari Z; Harefuah; 2012 Dec; 151(12):709-14, 719. PubMed ID: 23330266 [TBL] [Abstract][Full Text] [Related]
16. Boceprevir and telaprevir in the management of hepatitis C virus-infected patients. Butt AA; Kanwal F Clin Infect Dis; 2012 Jan; 54(1):96-104. PubMed ID: 22156853 [TBL] [Abstract][Full Text] [Related]
17. Effect of telaprevir on the pharmacokinetics of cyclosporine and tacrolimus. Garg V; van Heeswijk R; Lee JE; Alves K; Nadkarni P; Luo X Hepatology; 2011 Jul; 54(1):20-7. PubMed ID: 21618566 [TBL] [Abstract][Full Text] [Related]
18. A review of drug interactions with boceprevir and telaprevir: implications for HIV and transplant patients. Wilby KJ; Greanya ED; Ford JA; Yoshida EM; Partovi N Ann Hepatol; 2012; 11(2):179-85. PubMed ID: 22345334 [TBL] [Abstract][Full Text] [Related]